Mansour Asieh, Aboeerad Maryam, Qorbani Mostafa, Hashemi Taheri Amir Pejman, Pajouhi Mohamad, Keshtkar Abbas Ali, Larijani Bagher, Mohajeri-Tehrani Mohammad Reza, Ganji Mohammad Reza
Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran.
BMC Nephrol. 2018 Jul 11;19(1):172. doi: 10.1186/s12882-018-0960-z.
Nephrolithiasis is a risk factor for Osteopenia and osteoporosis. Receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin (OPG) regulate bone remodeling and osteoclastogenesis. This study aimed to evaluate the relation between serum OPG, RANKL concentration, and bone mineral density (BMD) in patients with kidney stone disease.
Forty-four nephrolithiasis patients with either low bone mass or normal BMD (considered control group) were enrolled in this study. BMD was measured at lumbar spine (L1-L4) and femoral neck by dual-energy X-ray absorptiometry (DEXA). The serum OPG and RANKL were determined using the ELISA method.
The median levels of serum OPG were significantly higher in nephrolithiasis patients with low bone mass compared to the nephrolithiasis patients with normal BMD (3.9 pmol/l versus 3.1 pmol/l; P = 0.03), respectively. Negative correlation was detected between bone densities of femoral neck and OPG in patients with nephrolithiasis (r = -.0344, P = 0.02).
The present study showed that high serum fasting OPG levels may be indicative of femoral neck BMD in patients with nephrolithiasis.
肾结石是骨质减少和骨质疏松的一个危险因素。核因子κB受体活化因子配体（RANKL）和骨保护素（OPG）调节骨重塑和破骨细胞生成。本研究旨在评估肾结石病患者血清OPG、RANKL浓度与骨密度（BMD）之间的关系。
本研究纳入了44例骨质低或骨密度正常的肾结石患者（作为对照组）。采用双能X线吸收法（DEXA）测量腰椎（L1-L4）和股骨颈的骨密度。采用酶联免疫吸附测定（ELISA）法测定血清OPG和RANKL。
骨质低的肾结石患者血清OPG的中位数水平显著高于骨密度正常的肾结石患者（分别为3.9 pmol/l和3.1 pmol/l；P = 0.03）。肾结石患者股骨颈骨密度与OPG之间存在负相关（r = -0.344，P = 0.02）。
本研究表明，高血清空腹OPG水平可能提示肾结石患者的股骨颈骨密度。
